Alnylam Pharmaceuticals Inc. (ALNY)
Alnylam Skyrockets After Hitting A 'Best-Case Scenario' For Heart Drug
Alnylam stock catapulted Monday after its experimental heart-disease treatment topped expectations in a highly anticipated study.
Alnylam (ALNY) Soars 5.3%: Is Further Upside Left in the Stock?
Alnylam (ALNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Alnylam's heart disease drug meets main goal in late-stage study
Alnylam Pharmaceuticals said on Monday that its drug vutrisiran met the main goal in a late-stage study testing it as a treatment for a type of heart disease.
The 'Undercovered' Dozen From June 1-6
The "Undercovered" Dozen highlights twelve ideas from the previous month on stocks with limited coverage. Biotechs CRISPR Therapeutics, Voyager Therapeutics, and Alnylam Pharmaceuticals are covered along with Enovix, Uranium Royalty, Clover Health, and Haliburton. Many of the ideas included have not been discussed in months on the site. One of the ideas is actually first-ever coverage for this ticker.
June's Biotech Boom: 3 Stocks to Buy for a Summertime Surge
Wall Street regards the healthcare sector as a constant source of innovation, while biotechnology stands at the pinnacle of groundbreaking medical advancements. The long-term potential of robust biotech stocks to buy remains undeniable for investors.
Upcoming Pivotal HELIOS-B Data Looms Large For Alnylam's Valuation
Alnylam Pharmaceuticals, Inc. is set to release clinical data from its HELIOS-B study in late June/early July, and this will have a significant impact on the company's share price. The success of the study could drive the share price to the high-$200 range, while a failure could lead to a drop towards $100. The key question is whether HELIOS-B shows a meaningful efficacy benefit for Amvuttra versus a high bar established by rival compounds.
